Online inquiry

IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14393MR)

This product GTTS-WQ14393MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IFNA1 gene. The antibody can be applied in Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_024013.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439
UniProt ID P01562
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14393MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13764MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ10843MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ627MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 7F3com-2H2
GTTS-WQ13239MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-05335810
GTTS-WQ4914MR IVTScrip™ mRNA-Anti-TNFRSF17, C11D5.3 scFv-8A-F9Z CAR(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA C11D5.3 scFv-8A-F9Z CAR
GTTS-WQ13880MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ15509MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7665
GTTS-WQ157MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW